Journal of Clinical Oncology - McMaster Experts

publication venue for

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. 38:496-520. 2020
National Cancer Institute Breast Cancer Steering Committee Working Group Report on Meaningful and Appropriate End Points for Clinical Trials in Metastatic Breast Cancer. 36:3259-3268. 2018
Prostate Cancer Radiotherapy: An Evolving Paradigm. 36:2909-2913. 2018
Predictors of Unemployment After Breast Cancer Surgery: A Systematic Review and Meta-Analysis of Observational Studies. 36:1868-1879. 2018
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. 36:1521-1539. 2018
Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. 36:757-764. 2018
Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years. 36:563-571. 2018
Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay. 36:238-243. 2018
A grounded theory analysis of oncology nurses' perceptions of early palliative care in the context of ambulatory care.. 35:96-96. 2017
Novel malignant bowel obstruction (MBO) management program for women with advanced gynecological cancer.. 35:158-158. 2017
Nurses’ roles and responsibilities in the provision of early palliative care: A grounded theory study.. 35:98-98. 2017
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 35:3484-3515. 2017
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. 35:3097-3104. 2017
Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non–Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. 35:2960-2974. 2017
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. 35:2934-2941. 2017
Reply to J.A. Vargo et al, H.J.A. Adams et al, E. Hindié et al, and S. Kothari et al. 35:2854-2855. 2017
Reply to T.J. Powles et al. 35:2720-2721. 2017
Patient-Reported Outcomes 1 Year After Immediate Breast Reconstruction: Results of the Mastectomy Reconstruction Outcomes Consortium Study. 35:2499-2506. 2017
Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline. 35:2062-2081. 2017
Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. 35:1884-1890. 2017
Limited-Stage Hodgkin Lymphoma: Clarifying Uncertainty. 35:1760-1763. 2017
Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update. 35:1737-1743. 2017
Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. 35:1641-1649. 2017
Reply to L.B. Marks et al. 35:1258-1259. 2017
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor–Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. 35:1041-1048. 2017
Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. 35:668-680. 2017
Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. 34:4431-4442. 2016
PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy. 34:3914-3920. 2016
Phase II Weekly Vinblastine for Chemotherapy-Naïve Children With Progressive Low-Grade Glioma: A Canadian Pediatric Brain Tumor Consortium Study. 34:3537-3543. 2016
Innovations in American Society of Clinical Oncology Practice Guideline Development. 34:3213-3220. 2016
Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer. 34:2325-2332. 2016
Eight Cycles of ABVD Versus Four Cycles of BEACOPPescalated Plus Four Cycles of BEACOPPbaseline in Stage III to IV, International Prognostic Score ≥ 3, High-Risk Hodgkin Lymphoma: First Results of the Phase III EORTC 20012 Intergroup Trial. 34:2028-2036. 2016
Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. 34:1676-1688. 2016
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. 34:1034-1042. 2016
Prospective Evaluation of the 21-Gene Recurrence Score Assay for Breast Cancer Decision-Making in Ontario. 34:1065-1071. 2016
Sisyphean Efforts: Establishing the Correct Risk-Benefit Balance for Adjuvant Therapies. 34:895-897. 2016
Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From BOLERO-2. 34:419-426. 2016
Effects of adjuvant 5FU/oxaliplatin chemotherapy in individuals treated for colon cancer on cognitive and mobility function.. 34:750-750. 2016
Radiation of the Internal Mammary Nodes: Is There a Benefit?. 34:297-299. 2016
Cognitive Function in Patients With Colorectal Cancer Who Do and Do Not Receive Chemotherapy: A Prospective, Longitudinal, Controlled Study. 33:4085-4092. 2015
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 33:3488-3515. 2015
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of highly or moderately emetogenic chemotherapy (HEC, MEC).. 33:210-210. 2015
Economic Evaluation of Bevacizumab for the First-Line Treatment of Newly Diagnosed Glioblastoma Multiforme. 33:2296-2302. 2015
Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. 33:2035-2040. 2015
Physicians’ attitudes toward systematic symptom assessment and management: Results from all regional cancer centres in Ontario (Canada).. 33:e17678-e17678. 2015
Predicting Anthracycline Benefit: TOP2A and CEP17—Not Only but Also. 33:1680-1687. 2015
Lapatinib or Trastuzumab Plus Taxane Therapy for Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: Final Results of NCIC CTG MA.31. 33:1574-1583. 2015
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014. 33:654-656. 2015
Bronchoalveolar Lavage and Lung Biopsy in Patients With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: A Systematic Review and Meta-Analysis. 33:501-509. 2015
Duration of Androgen Suppression Before Radiotherapy for Localized Prostate Cancer: Radiation Therapy Oncology Group Randomized Clinical Trial 9910. 33:332-339. 2015
Magnetic Resonance Imaging Improves Breast Screening Sensitivity in BRCA Mutation Carriers Age ≥ 50 Years: Evidence From an Individual Patient Data Meta-Analysis. 33:349-356. 2015
Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. 33:265-271. 2015
Diagnostic Criteria for the Classification of Cancer-Associated Weight Loss. 33:90-99. 2015
Impact of Reirradiation of Painful Osseous Metastases on Quality of Life and Function: A Secondary Analysis of the NCIC CTG SC.20 Randomized Trial. 32:3867-3873. 2014
Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole-Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. 32:3810-3816. 2014
How Long to Treat Acute Venous Thrombosis in Cancer: Can Treatment Be Personalized?. 32:3586-3587. 2014
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12. 32:3490-3496. 2014
Identifying targets for outpatient palliative care wait times in Ontario.. 32:258-258. 2014
Population-based standardized symptom screening: Cancer Care Ontario’s Edmonton Symptom Assessment System and performance status initiatives.. 32:56-56. 2014
Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. 32:3436-3448. 2014
Randomized Trial of a Telephone-Based Weight Loss Intervention in Postmenopausal Women With Breast Cancer Receiving Letrozole: The LISA Trial. 32:2231-2239. 2014
Reply to J. Menczer. 32:2114-2114. 2014
Limited-Stage Hodgkin Lymphoma: Managing Uncertainty. 32:1180-1182. 2014
Cost Effectiveness of EML4-ALK Fusion Testing and First-Line Crizotinib Treatment for Patients With Advanced ALK-Positive Non–Small-Cell Lung Cancer. 32:1012-1019. 2014
Cytogenetic Prognostication Within Medulloblastoma Subgroups. 32:886-896. 2014
Impact of Wait Times on Survival for Women With Uterine Cancer. 32:27-33. 2014
Symptoms and Cancer Outcome in Adjuvant Endocrine Therapy for Breast Cancer: Why Are They Associated?. 31:4476-4476. 2013
Randomized, Double-Blind, Placebo-Controlled, Phase III Chemoprevention Trial of Selenium Supplementation in Patients With Resected Stage I Non–Small-Cell Lung Cancer: ECOG 5597. 31:4179-4187. 2013
Interim Cosmetic and Toxicity Results From RAPID: A Randomized Trial of Accelerated Partial Breast Irradiation Using Three-Dimensional Conformal External Beam Radiation Therapy. 31:4038-4045. 2013
Randomized Trial of Decongestive Lymphatic Therapy for the Treatment of Lymphedema in Women With Breast Cancer. 31:3758-3763. 2013
Selective Application of a Test Based on Risk: Using Limited Resources Wisely. 31:2847-2848. 2013
Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. 31:2927-2935. 2013
Surrogacy of Financial Conflicts of Interest. 31:2645-2647. 2013
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 31:2189-2204. 2013
Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial. 31:1398-1404. 2013
Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. 31:1164-1171. 2013
Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. 31:1202-1210. 2013
Comparative Effectiveness Research Paradigm: Implications for Systematic Reviews and Clinical Practice Guidelines. 30:4202-4207. 2012
Special Series on Comparative Effectiveness Research: Challenges to Real-World Solutions to Quality Improvement in Personalized Medicine. 30:4188-4191. 2012
Policy Directives in Cancer, Organizational Responses, and the Need for Evaluation. 30:3907-3908. 2012
Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II Study. 30:3396-3401. 2012
Hepatitis B, Rituximab, Screening, and Prophylaxis: Effectiveness and Cost Effectiveness. 30:3155-3157. 2012
American Society of Clinical Oncology Clinical Practice Guidelines: Formal Systematic Review–Based Consensus Methodology. 30:3136-3140. 2012
Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer. 30:2906-2911. 2012
Personalized Medicine: What Exactly Is It and Can We Truly Measure It?. 30:2173-2174. 2012
Method to Our Madness or Madness in Our Methods? Pitfalls in Trial Methodology. 30:2025-2027. 2012
Phase II Study of Ganitumab, a Fully Human Anti–Type-1 Insulin-Like Growth Factor Receptor Antibody, in Patients With Metastatic Ewing Family Tumors or Desmoplastic Small Round Cell Tumors. 30:1849-1856. 2012
Is Colon Cancer Survival Influenced by Tumor Location?. 30:1732-1733. 2012
Funding Oncology Clinical Trials: Are Cooperative Group Trials Sustainable?. 30:1456-1461. 2012
Prospective Study of 2-[18F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study. 30:1274-1279. 2012
Reply to M. Jefford et al and C.T. Stricker et al. 30:1393-1394. 2012
Reply to P. Ameri et al. 30:1396-1396. 2012
Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90Y-DOTA]-TOC Versus [90Y-DOTA]-TOC Plus [177Lu-DOTA]-TOC in Neuroendocrine Cancers. 30:1100-1106. 2012
Opioid Prescription After Pain Assessment: A Population-Based Cohort of Elderly Patients With Cancer. 30:1095-1099. 2012
Consistency in the Analysis and Reporting of Primary End Points in Oncology Randomized Controlled Trials From Registration to Publication: A Systematic Review. 30:210-216. 2012
Evolution of Clinical Trials Registries. 30:131-133. 2012
Insulin- and Obesity-Related Variables in Early-Stage Breast Cancer: Correlations and Time Course of Prognostic Associations. 30:164-171. 2012
Molecular Detection of Tumor Cells in Regional Lymph Nodes Is Associated With Disease Recurrence and Poor Survival in Node-Negative Colorectal Cancer: A Systematic Review and Meta-Analysis. 30:60-70. 2012
Evaluating Survivorship Care Plans: Results of a Randomized, Clinical Trial of Patients With Breast Cancer. 29:4755-4762. 2011
Perspectives of Patients on the Utility of Electronic Patient-Reported Outcomes on Cancer Care. 29:4213-4214. 2011
Management of Hot Flashes in Patients Who Have Breast Cancer With Venlafaxine and Clonidine: A Randomized, Double-Blind, Placebo-Controlled Trial. 29:3862-3868. 2011
Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR Therapy in the Adjuvant Treatment of Early-Stage Breast Cancer in Postmenopausal Women: NCIC CTG MA.14. 29:3869-3876. 2011
Elevated Bone Turnover Predicts for Bone Metastasis in Postmenopausal Breast Cancer: Results of NCIC CTG MA.14. 29:3605-3610. 2011
Bortezomib Added to R-CVP Is Safe and Effective for Previously Untreated Advanced-Stage Follicular Lymphoma: A Phase II Study by the National Cancer Institute of Canada Clinical Trials Group. 29:3396-3401. 2011
Reply to C. McCowan et al. 29:3492-3493. 2011
Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. 29:3278-3285. 2011
Reply to J.-J. de Arriba, et al. 29:2833-2834. 2011
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. 29:2416-2423. 2011
Randomized, Placebo-Controlled, Phase III Study of First-Line Oxaliplatin-Based Chemotherapy Plus PTK787/ZK 222584, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Metastatic Colorectal Adenocarcinoma. 29:1997-2003. 2011
Long-Term Follow-Up of Women in Trials of Adjuvant Therapy for Breast Cancer: Is It Still Important?. 29:1651-1652. 2011
Trajectory of Performance Status and Symptom Scores for Patients With Cancer During the Last Six Months of Life. 29:1151-1158. 2011
Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer. 29:1075-1082. 2011
Cardiac Troponin Cutoffs: The Importance of Assay Sensitivity and the Patient Population. 29:e177-e177. 2011
Multicenter, Randomized, Cross-Over Clinical Trial of Venlafaxine Versus Gabapentin for the Management of Hot Flashes in Breast Cancer Survivors. 28:5147-5152. 2010
American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer. 28:4996-5010. 2010
Case Report: Celiac Disease Masquerading As Bone Metastasis in a 29-Year-Old Woman. 28:e623-e625. 2010
Genome-Wide Associations and Functional Genomic Studies of Musculoskeletal Adverse Events in Women Receiving Aromatase Inhibitors. 28:4674-4682. 2010
Reply to D.J. Stewart. 28:e651-e651. 2010
Obesity and Hormone Therapy in Breast Cancer: An Unfinished Puzzle. 28:3405-3407. 2010
Defective Mismatch Repair As a Predictive Marker for Lack of Efficacy of Fluorouracil-Based Adjuvant Therapy in Colon Cancer. 28:3219-3226. 2010
Reply to C.D. Atkins. 28:e264-e264. 2010
Randomized Phase II Trials: Inevitable or Inadvisable?. 28:2641-2647. 2010
Conventional and Complementary Therapies: A Tale of Two Research Standards?. 28:1979-1981. 2010
Disseminated Tumor Embolism From Breast Cancer Leading to Multiorgan Failure. 28:e180-e183. 2010
Optimizing the Delivery of Targeted Research: An Opportunity for Comparative Effectiveness Research. 28:1089-1091. 2010
Phase I/II Trial of Metronomic Chemotherapy With Daily Dalteparin and Cyclophosphamide, Twice-Weekly Methotrexate, and Daily Prednisone As Therapy for Metastatic Breast Cancer Using Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor Levels As Markers of Response. 28:723-730. 2010
Generalizing the Results of Cancer Clinical Trials. 28:187-189. 2010
Cyclophosphamide, Epirubicin, and Fluorouracil Versus Dose-Dense Epirubicin and Cyclophosphamide Followed by Paclitaxel Versus Doxorubicin and Cyclophosphamide Followed by Paclitaxel in Node-Positive or High-Risk Node-Negative Breast Cancer. 28:77-82. 2010
Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study. 28:49-55. 2010
Evidence-Based Approach to the Introduction of Positron Emission Tomography in Ontario, Canada. 27:5607-5613. 2009
Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. 27:5109-5114. 2009
New Antithrombotic Drugs: Potential for Use in Oncology. 27:4912-4918. 2009
Prevention of Thrombosis in Ambulatory Patients With Cancer. 27:4885-4888. 2009
Are HER2 and TOP2A Useful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?. 27:3875-3876. 2009
Presentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings. 27:3938-3944. 2009
Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer. 27:3757-3763. 2009
American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. 27:3235-3258. 2009
Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study. 27:3097-3103. 2009
Prognostic Tools for Cancer Survival: A Secondary Role for Quality-of-Life Measurement. 27:2902-2904. 2009
Lack of Comprehension of Common Prostate Cancer Terms in an Underserved Population. 27:2015-2021. 2009
Are Cancer-Related Decision Aids Effective? A Systematic Review and Meta-Analysis. 27:974-985. 2009
In Reply. 27:647-647. 2009
Randomized, Double-Blind, Placebo-Controlled Trial of Epoetin Alfa in Men With Castration-Resistant Prostate Cancer and Anemia. 27:644-646. 2009
Tumor Cavitation: Impact on Objective Response Evaluation in Trials of Angiogenesis Inhibitors in Non–Small-Cell Lung Cancer. 27:404-410. 2009
Impact of Caring for a Child With Cancer on Parents’ Health-Related Quality of Life. 26:5884-5889. 2008
Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer. 26:5465-5476. 2008
Registries That Show Efficacy: Good, but Not Good Enough. 26:5316-5319. 2008
Availability and Use of Palliative Care and End-of-Life Services for Pediatric Oncology Patients. 26:4646-4650. 2008
Identification of Cancer Care and Protocol Characteristics Associated With Recruitment in Breast Cancer Clinical Trials. 26:4458-4465. 2008
Phase II Study of Erlotinib in Recurrent or Metastatic Endometrial Cancer: NCIC IND-148. 26:4319-4325. 2008
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. 26:4268-4275. 2008
American Society of Clinical Oncology Clinical Practice Guidelines: Opportunities and Challenges. 26:4022-4026. 2008
Phase II Stopping Rules That Employ Response Rates and Early Progression. 26:3715-3720. 2008
Dual-Agent Molecular Targeting of the ErbB2 Receptor: Killing One Bird With Two Stones. 26:3301-3302. 2008
In Reply. 26:2788-2788. 2008
Stopping Trials for Benefit Can (Sometimes) Benefit Patients. 26:2787-2788. 2008
In Reply. 26:2596-2597. 2008
Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17. 26:1956-1964. 2008
Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen. 26:1948-1955. 2008
Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials Group. 26:1871-1878. 2008
Ontario Cancer Research Ethics Board: Lessons Learned From Developing a Multicenter Regional Institutional Review Board. 26:1479-1482. 2008
Nomograms to Predict Serious Adverse Events in Phase II Clinical Trials of Molecularly Targeted Agents. 26:1324-1330. 2008
A for Effort: Learning From the Application of the GRADE Approach to Cancer Guideline Development. 26:1025-1026. 2008
Absence of Secondary Malignant Neoplasms in Children With High-Risk Acute Lymphoblastic Leukemia Treated With Dexrazoxane. 26:1106-1111. 2008
HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy. 26:736-744. 2008
Is There a Role for Positron Emission Tomography in Breast Cancer Staging?. 26:712-720. 2008
Preface to Second Review Issue on Breast Cancer. 26:695-695. 2008
Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer: A National Cancer Institute Conference. 26:791-797. 2008
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study. 26:242-245. 2008
Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16. 26:37-43. 2008
Randomized Trials in Oncology Stopped Early for Benefit. 26:18-19. 2008
In Reply. 25:5667-5667. 2007
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer. 25:5490-5505. 2007
Cancer Care Ontario and American Society of Clinical Oncology Adjuvant Chemotherapy and Adjuvant Radiation Therapy for Stages I-IIIA Resectable Non–Small-Cell Lung Cancer Guideline. 25:5506-5518. 2007
Neuropsychological Outcomes From a Randomized Trial of Triple Intrathecal Chemotherapy Compared With 18 Gy Cranial Radiation As CNS Treatment in Acute Lymphoblastic Leukemia: Findings From Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. 25:4914-4921. 2007
Incidence of Metastatic Nonseminomatous Germ Cell Tumor Outside the Boundaries of a Modified Postchemotherapy Retroperitoneal Lymph Node Dissection. 25:4365-4369. 2007
Phase II Study of Vandetanib or Placebo in Small-Cell Lung Cancer Patients After Complete or Partial Response to Induction Chemotherapy With or Without Radiation Therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. 25:4278-4284. 2007
Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands. 25:3978-3984. 2007
Role of Gonadotropin-Releasing Hormone Analog in the Management of Male Metastatic Breast Cancer Is Uncertain. 25:3787-3787. 2007
Predictive and Pharmacodynamic Biomarker Studies in Tumor and Skin Tissue Samples of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Erlotinib. 25:2184-2190. 2007
Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. 25:2127-2132. 2007
Long-Term Clinical Outcome After Postchemotherapy Retroperitoneal Lymph Node Dissection in Men With Residual Teratoma. 25:1033-1037. 2007
Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non–Small-Cell Lung Cancer With Disease-Related Anemia. 25:1027-1032. 2007
Economic Evaluation in the Journal of Clinical Oncology: Past, Present, and Future. 25:614-616. 2007
Comment on ASCO-ESMO Consensus Statement on Quality Cancer Care. 24:5613-5614. 2006
Meta-Analysis of Randomized Controlled Trials of Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor After Autologous and Allogeneic Stem Cell Transplantation. 24:5207-5215. 2006
Phase II Trial Evaluating the Palliative Benefit of Second-Line Zoledronic Acid in Breast Cancer Patients With Either a Skeletal-Related Event or Progressive Bone Metastases Despite First-Line Bisphosphonate Therapy. 24:4895-4900. 2006
In Reply. 24:4038a-4039. 2006
Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response. 24:3953-3958. 2006
Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17. 24:3629-3635. 2006
Health Status Measurements at Diagnosis As Predictors of Survival Among Adults With Brain Tumors. 24:3636-3643. 2006
In Reply. 24:3711-3712. 2006
Ten-Year Multi-Institutional Results of Breast-Conserving Surgery and Radiotherapy in BRCA1/2-Associated Stage I/II Breast Cancer. 24:2437-2443. 2006
Phase III Trial of an Emulsion Containing Trolamine for the Prevention of Radiation Dermatitis in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Trial 99-13. 24:2092-2097. 2006
In Utero Exposure to Chemotherapy: Effect on Cardiac and Neurologic Outcome. 24:e16-e17. 2006
Incidence, Risk Factors, and Outcomes of Catheter-Related Thrombosis in Adult Patients With Cancer. 24:1404-1408. 2006
Quality of Randomized Controlled Trials Reporting in the Primary Treatment of Brain Tumors. 24:1136-1144. 2006
Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. 24:848-855. 2006
The Importance of Reporting Patient Recruitment Details in Phase III Trials. 24:843-845. 2006
Overstated Conclusions of a Pooled Analysis of Bevacizumab in Colon Cancer. 24:528-529. 2006
In Reply:. 23:8915-8916. 2005
In Reply:. 23:8918-8919. 2005
Trastuzumab Cardiac Side Effects: Only Time Will Tell. 23:7775-7776. 2005
Assessment of Quality of Life in MA.17: A Randomized, Placebo-Controlled Trial of Letrozole After 5 Years of Tamoxifen in Postmenopausal Women. 23:6931-6940. 2005
In Reply:. 23:7244-7244. 2005
In Reply:. 23:7250-7250. 2005
In Reply:. 23:6267-6267. 2005
In Reply:. 23:6273-6274. 2005
Incidence and Prognostic Impact of Amenorrhea During Adjuvant Therapy in High-Risk Premenopausal Breast Cancer: Analysis of a National Cancer Institute of Canada Clinical Trials Group Study—NCIC CTG MA.5. 23:6002-6008. 2005
Is Leptin a Mediator of Adverse Prognostic Effects of Obesity in Breast Cancer?. 23:6037-6042. 2005
Randomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer. 23:6132-6138. 2005
Randomized Phase III Study of Docetaxel Compared With Paclitaxel in Metastatic Breast Cancer. 23:5542-5551. 2005
Aromatase Inhibitors in Adjuvant Therapy of Breast Cancer: Before, Instead of, or Beyond Tamoxifen. 23:4850-4852. 2005
Randomized Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With Cyclophosphamide, Methotrexate, and Fluorouracil in Premenopausal Women With Node-Positive Breast Cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. 23:5166-5170. 2005
Reliance on Hormone Receptor Assays of Surgical Specimens May Compromise Outcome in Patients With Breast Cancer. 23:5148-5154. 2005
Randomized Comparison of ABVD Chemotherapy With a Strategy That Includes Radiation Therapy in Patients With Limited-Stage Hodgkin’s Lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. 23:4634-4642. 2005
Randomized Placebo-Controlled Study of Low-Dose Warfarin for the Prevention of Central Venous Catheter–Associated Thrombosis in Patients With Cancer. 23:4063-4069. 2005
Analysis of Treatment Practices for Elderly Cancer Patients in Ontario, Canada. 23:3802-3810. 2005
In Reply:. 23:3633-3634. 2005
Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer. 23:2918-2925. 2005
Randomized Phase III Study of Matrix Metalloproteinase Inhibitor BMS-275291 in Combination With Paclitaxel and Carboplatin in Advanced Non-Small-Cell Lung Cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. 23:2831-2839. 2005
Standards of Proof, Standards of Practice, and Proof of Standards: A Tale of Two Trials. 23:2583-2585. 2005
Randomized Comparison of Low Molecular Weight Heparin and Coumarin Derivatives on the Survival of Patients With Cancer and Venous Thromboembolism. 23:2123-2129. 2005
Physician/Patient Decision Aids for Adjuvant Therapy. 23:1627-1630. 2005
Preface to Special Edition on Breast Cancer. 23:1595-1595. 2005
Use of Conventional Radiation Therapy As Part of Breast-Conserving Treatment. 23:1718-1725. 2005
The Metrics of Clinical Trials. 23:1589-1590. 2005
Randomized Trial Comparing Iridium Implant Plus External-Beam Radiation Therapy With External-Beam Radiation Therapy Alone in Node-Negative Locally Advanced Cancer of the Prostate. 23:1192-1199. 2005
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors As Adjuvant Therapy for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Status Report 2004. 23:619-629. 2005
American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. 23:619-629. 2005
Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study. 23:585-590. 2005
Practitioners As Experts: The Influence of Practicing Oncologists “in-the-Field” on Evidence-Based Guideline Development. 23:113-119. 2005
Radiation Therapy and Tamoxifen: Concurrent or Sequential? That Is the Question. 23:1-4. 2005
Health-Related Quality of Life and Psychosocial Status in Breast Cancer Prognosis: Analysis of Multiple Variables. 22:4184-4192. 2004
Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care’s Gastrointestinal Cancer Disease Site Group. 22:3395-3407. 2004
Prophylactic Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Decrease Febrile Neutropenia After Chemotherapy in Children With Cancer: A Meta-Analysis of Randomized Controlled Trials. 22:3350-3356. 2004
International Assessment of the Quality of Clinical Practice Guidelines in Oncology Using the Appraisal of Guidelines and Research and Evaluation Instrument. 22:2000-2007. 2004
Low Molecular Weight Heparin, Therapy With Dalteparin, and Survival in Advanced Cancer: The Fragmin Advanced Malignancy Outcome Study (FAMOUS). 22:1944-1948. 2004
In Reply:. 22:1343-1344. 2004
Skeletal Morbidity in Childhood Acute Lymphoblastic Leukemia. 22:1215-1221. 2004
Safety of Treatment of Metastatic Breast Cancer With Trastuzumab Beyond Disease Progression. 22:1063-1070. 2004
Economics of Preoperative Radiotherapy With Total Mesorectal Excision: What Can We Learn From the Dutch Experience?. 22:217-219. 2004
Phase III Study of N,N-Diethyl-2-[4-(Phenylmethyl) Phenoxy]Ethanamine (BMS-217380-01) Combined With Doxorubicin Versus Doxorubicin Alone in Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19. 22:269-276. 2004
The Combination of p53 Mutation and neu/erbB-2 Amplification Is Associated With Poor Survival in Node-Negative Breast Cancer. 22:86-96. 2004
Researching the Cost of Research. 21:4081-4082. 2003
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel. 21:3965-3971. 2003
Risk of Acute Leukemia Following Epirubicin-Based Adjuvant Chemotherapy: A Report From the National Cancer Institute of Canada Clinical Trials Group. 21:3066-3071. 2003
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma. 21:2636-2644. 2003
American Society of Clinical Oncology Technology Assessment Working Group Update: Use of Aromatase Inhibitors in the Adjuvant Setting. 21:2597-2599. 2003
Diet and Breast Cancer: Evidence That Extremes in Diet Are Associated With Poor Survival. 21:2500-2507. 2003
CORRESPONDENCE. 21:2445-2446. 2003
Quality of Life in a Randomized Trial of Group Psychosocial Support in Metastatic Breast Cancer: Overall Effects of the Intervention and an Exploration of Missing Data. 21:1944-1951. 2003
CORRESPONDENCE. 21:1895-1895. 2003
Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group. 21:1740-1745. 2003
Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-Line Therapy in Malignant Pleural Mesothelioma. 21:1556-1561. 2003
Optimal Chemotherapy for Women With Breast Cancer: The Plot Thickens. 21:963-964. 2003
Final Results of a Randomized Phase III Trial Comparing Cyclophosphamide, Epirubicin, and Fluorouracil With a Dose-Intensified Epirubicin and Cyclophosphamide + Filgrastim as Neoadjuvant Treatment in Locally Advanced Breast Cancer: An EORTC-NCIC-SAKK Multicenter Study. 21:843-850. 2003
Shared Treatment Decision Making: What Does It Mean to Physicians?. 21:932-936. 2003
Does Delay in Starting Treatment Affect the Outcomes of Radiotherapy? A Systematic Review. 21:555-563. 2003
Management and Outcome Differences in Supraglottic Cancer Between Ontario, Canada, and the Surveillance, Epidemiology, and End Results Areas of the United States. 21:496-505. 2003
neu/erbB-2 Overexpression and Response to Hormonal Therapy in Premenopausal Women in the Adjuvant Breast Cancer Setting: Will It Play in Peoria? Part II. 21:399-400. 2003
Adjuvant Therapy for Premenopausal Women With Breast Cancer: Is It Time for Another Paradigm Shift?. 20:4611-4614. 2002
Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin’s Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen. 20:4649-4654. 2002
A Trial of Two Questions. 20:4135-4138. 2002
Do quality-of-life randomized clinical trials support clinicians in their decision-making? Reply. 20:4127-4127. 2002
Use of Epoetin in Patients With Cancer: Evidence-Based Clinical Practice Guidelines of the American Society of Clinical Oncology and the American Society of Hematology. 20:4083-4107. 2002
Phase I Clinical and Pharmacokinetic Study of Pemetrexed and Carboplatin in Patients With Malignant Pleural Mesothelioma. 20:3533-3544. 2002
American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002. 20:3317-3327. 2002
Beyond the Development of Quality-of-Life Instruments: Where Do We Go From Here?. 20:2215-2216. 2002
Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.. 20:1677-1682. 2002
INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.. 20:1167-1174. 2002
Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix.. 20:966-972. 2002
Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. 20:205-213. 2002
Campath-1H Treatment of T-Cell Prolymphocytic Leukemia in Patients for Whom at Least One Prior Chemotherapy Regimen Has Failed. 20:205-213. 2002
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. 20:42-51. 2002
Fasting Insulin and Outcome in Early-Stage Breast Cancer: Results of a Prospective Cohort Study. 20:42-51. 2002
Phase I Study of Combination Topotecan and Carboplatin in Pediatric Solid Tumors. 20:88-95. 2002
Phase I Study of Combination Topotecan and Carboplatin in Pediatric Solid Tumors. 20:88-95. 2002
Use of ErbB-1 and ErbB-2 to Select Endocrine Therapy for Breast Cancer: Will It Play in Peoria?. 19:3795-3797. 2001
Funding New Cancer Drugs in Ontario: Closing the Loop in the Practice Guidelines Development Cycle. 19:3392-3396. 2001
Strategies to Manage the Adverse Effects of Oral Morphine: An Evidence-Based Report. 19:2542-2554. 2001
Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology*. 19:1539-1569. 2001
Anthracycline Adjuvant Chemotherapy: How Much Is Enough?. 19:599-601. 2001
Bleomycin-Induced Lung Toxicity and Pentoxifylline. 19:597-598. 2001
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials. 19:558-567. 2001
Health-Related Quality of Life in Survivors of Wilms’ Tumor and Advanced Neuroblastoma: A Cross-Sectional Study. 18:3280-3287. 2000
Incidence of Recurrent Thromboembolic and Bleeding Complications Among Patients With Venous Thromboembolism in Relation to Both Malignancy and Achieved International Normalized Ratio: A Retrospective Analysis. 18:3078-3083. 2000
Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8. 18:2385-2394. 2000
Does Locoregional Radiation Therapy Improve Survival in Breast Cancer? A Meta-Analysis. 18:1220-1229. 2000
Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study. 17:3431-3437. 1999
Placebo-Controlled Trial of 13-cis-Retinoic Acid Activity on Retinoic Acid Receptor-Beta Expression in a Population at High Risk: Implications for Chemoprevention of Lung Cancer. 17:3546-3552. 1999
Risk of Menopause During the First Year After Breast Cancer Diagnosis. 17:2365-2365. 1999
Essence of Evidence-Based Medicine: A Case Report. 17:1969-1969. 1999
Mastectomy or Lumpectomy? Helping Women Make Informed Choices. 17:1727-1727. 1999
Science, Language, Intuition, and the Many Meanings of Quality of Life. 17:1651-1651. 1999
Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patients With Advanced Non–Small-Cell Lung Cancer: A Phase II Study. 17:1194-1194. 1999
Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis. 17:120-120. 1999
Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer - In reply. 16:3917-3917. 1998
Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.. 16:3524-3527. 1998
Relevant clinical end points in biphosphonate trials.. 16:3204-3205. 1998
Quality-adjusted time without symptoms or toxicity analysis of interferon maintenance in multiple myeloma.. 16:2834-2839. 1998
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. 16:2651-2658. 1998
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.. 16:2651-2658. 1998
Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.. 16:2272-2279. 1998
Progress of clinical oncology guidelines development using the Practice Guidelines Development Cycle: the role of practitioner feedback.. 16:1226-1231. 1998
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. 16:1174-1178. 1998
Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.. 16:1174-1178. 1998
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.. 16:800-802. 1998
Breast cancer patients' attitudes about rationing postlumpectomy radiation therapy: applicability of trade-off methods to policy-making.. 15:3192-3200. 1997
Lung cancer practice guidelines: lessons learned and issues addressed by the Ontario Lung Cancer Disease Site Group.. 15:3049-3059. 1997
Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.. 15:2302-2311. 1997
Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease.. 15:2322-2328. 1997
Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin.. 15:1897-1905. 1997
Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group.. 15:1638-1645. 1997
Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective.. 15:632-639. 1997
Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.. 14:2731-2737. 1996
Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group study.. 14:2709-2712. 1996
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. 14:2083-2090. 1996
Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.. 14:2083-2090. 1996
Economic evaluation of allogeneic bone marrow transplantation: a rudimentary model to generate estimates for the timely formulation of clinical policy.. 14:1413-1420. 1996
Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant.. 14:1327-1332. 1996
Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits?. 14:997-1006. 1996
Randomized phase II comparison of standard CHOP with weekly CHOP in elderly patients with non-Hodgkin's lymphoma.. 13:2386-2393. 1995
Randomized trial of interferon maintenance in multiple myeloma: a study of the National Cancer Institute of Canada Clinical Trials Group.. 13:2354-2360. 1995
Breast irradiation postlumpectomy: development and evaluation of a decision instrument.. 13:847-853. 1995
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation.. 13:502-512. 1995
Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: an economic evaluation.. 13:42-46. 1995
Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer.. 12:2648-2653. 1994
Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.. 12:689-694. 1994
Informed consent in compliance studies.. 11:2457-2458. 1993
Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?. 11:1866-1872. 1993
Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group study.. 11:1241-1244. 1993
THE PHYSICIAN AS THE PATIENTS ADVOCATE. 11:1011-1013. 1993
The Head and Neck Radiotherapy Questionnaire: a morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer.. 11:863-872. 1993
Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group.. 11:336-344. 1993
The HER-2/neu oncogene in breast cancer: so what is new?. 10:1034-1036. 1992
A comprehensive multiattribute system for classifying the health status of survivors of childhood cancer.. 10:923-928. 1992
Combined modality therapy of Hodgkin's disease: 10-year results of National Cancer Institute of Canada Clinical Trials Group multicenter clinical trial.. 9:1983-1993. 1991
Dose intensity and lymphoma.. 9:1511-1511. 1991
Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.. 9:729-735. 1991
The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma.. 9:339-347. 1991
When is a prognostic factor useful? A guide for the perplexed.. 9:348-356. 1991
A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer.. 8:1217-1225. 1990
Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial.. 8:203-208. 1990
Quality of life in stage II breast cancer: an instrument for clinical trials.. 6:1798-1810. 1988
Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a National Cancer Institute of Canada Clinical Trials Group report.. 6:1254-1263. 1988
Methotrexate/fluorouracil scheduling influences normal tissue toxicity but not antitumor effects in patients with squamous cell head and neck cancer: results from a randomized trial.. 6:963-968. 1988
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.. 6:633-641. 1988
Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia.. 5:722-730. 1987
Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma.. 5:635-640. 1987
Bench-to-bedside research and the human tumor stem-cell assay--bridging the credibility gap.. 4:1730-1731. 1986
DOSE INTENSITY AND RESPONSE - REPLY. 4:1865-1865. 1986
Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer.. 4:1162-1170. 1986
Lack of evidence for a role of chemotherapy in the routine management of locally advanced head and neck cancer.. 4:1121-1126. 1986
Tetracycline sclerosis in the management of malignant pericardial effusion.. 3:1678-1682. 1985
Combination chemotherapy with bleomycin, etoposide, and cisplatin in metastatic non-small-cell lung cancer.. 3:1478-1485. 1985
Methodologic issues in trials of antiemetics.. 2:484-487. 1984
Combined modality induction therapy without maintenance chemotherapy for small cell carcinoma of the lung.. 2:294-304. 1984
Prospective randomized trial of one-hour sequential versus simultaneous methotrexate plus 5-fluorouracil in advanced and recurrent squamous cell head and neck cancer.. 1:787-792. 1983
5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors. 2019
A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies. 2019
A randomized study comparing physician-directed or fixed-dose dexamethasone replacement following incomplete steroid premedication for docetaxel chemotherapy. 2019
Active surveillance in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). 2019
Association of immune-related adverse events (irAEs) with clinical benefit in patients with metastatic urothelial carcinoma (mUC) treated with immune-checkpoint inhibitors (ICIs). 2019
CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC). 2019
Cctg MA.39 tailor RT: A randomized trial of regional radiotherapy in biomarker low-risk node-positive breast cancer (NCT03488693). 2019
Cost disparities with age in the treatment of advanced non-small cell lung cancer (NSCLC) in Ontario, Canada. 2019
First-line PD(L)1 inhibitors for platinum-ineligible advanced urothelial carcinoma (aUC). 2019
Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study. 2019
The ESCAPADE Study: Early supportive care for advanced cancer patients, assessing care delivery and provider engagement. 2019
weekly administration of bone-targeted agents (denosumab, zoledronate, or pamidronate) in patients with bone metastases from either breast or castration resistant prostate cancer. 2019
Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis). 2019
First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC). 2019
Impact of body mass index (BMI) on treatment outcomes to immune checkpoint blockade (ICB) in metastatic renal cell carcinoma (mRCC). 2019
Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma. 2019
Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs). 2019
Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors. 2019
CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC). 2019
Simultaneous resection of colorectal cancer with synchronous liver metastases: A survey-based analysis. 2019
Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study. 2019
Oncologists and medical assistance in dying: Where do we stand? 2018
Active identification of patients appropriate for palliative care: Impact on use of palliative care and home care resources. 2018
Does the risk of emergency department visits and hospitalizations during systemic therapy for cancer influence patient decisions regarding treatment? 2018
Does the risk of emergency department visits and hospitalizations during systemic therapy for cancer influence patients’ decisions regarding treatment? 2018
Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases. The long-term results of a randomized controlled trial (PET-CT Imaging prior to liver resection for colorectal adenocarcinoma metastases). 2018
Evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction. 2018
Ascertaining cancer survivors in Ontario using the Ontario Cancer Registry and administrative data. 2018
Evaluating the impact of survivorship models on health system resources and costs. 2018
The impact of a well breast cancer patient transition model of care on oncologists’ practice. 2018
C-reactive protein as a prognostic factor in advanced urothelial carcinoma receiving chemotherapy or immunotherapy. 2018
Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials. 2018
New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab. 2018
Nivolumab demonstrates benefit over nomogram-predicted 12-month survival as salvage therapy for metastatic urothelial carcinoma. 2018
Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study. 2018
Statin use and outcomes of patients (pts) with metastatic castration resistant prostate cancer (mCRPC) being treated with abiraterone (Abi). 2018
Effect of PET-CT on disease recurrence and its management in patients with potentially resectable colorectal cancer liver metastases: The long-term results of a randomized control trial. 2018
Major arterial resection for stage 3 adenocarcinoma of the pancreas. 2018
Systematic review and meta-analysis of the effect of pre-operative PET/PET-CT in the management of patients with potentially resectable colorectal cancer liver metastasis. 2018
Code status communication training in Canadian postgraduate oncology programs: A needs assessment survey. 2017
The PULSES project: Teaching the vital elements of code status discussions to oncology residents. 2017
A meta-analysis of trials of etoposide plus platinum agent versus irinotecan/topotecan plus platinum agent in first-line therapy of extensive stage small cell lung cancer (ES SCLC). 2017
Abiraterone +/- cabazitaxel in defining complete response in prostatectomy (ACDC-RP) trial. 2017
Association between progression-free survival and health-related quality of life in oncology: A systematic review and regression analysis. 2017
Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape. 2017
Clinical outcomes according to ethnicity in patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). 2017
Developing and piloting an electronic telephone triage application. 2017
Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). 2017
NCI Breast Cancer Steering Committee Working Group (WG) report on meaningful and appropriate endpoints for clinical trials (CT) in metastatic breast cancer (MBC). 2017
Neurocognitive functions and psychological distress in young adults with cancer (YAC): A prospective, longitudinal study. 2017
Nomogram to assess survival benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials. 2017
Phase I study of oncolytic virus (OV) MG1 maraba/MAGE-A3 (MG1MA3), with and without transgenic MAGE-A3 adenovirus vaccine (AdMA3) in incurable advanced/metastatic MAGE-A3-expressing solid tumours: CCTG IND.214. 2017
Phase II study of individualized sunitinib (SUN) as first-line therapy for metastatic renal cell cancer. 2017
Rates of trastuzumab-associated cardiotoxicity in patients with HER2-positive breast cancer at a tertiary cancer centre. 2017
Retrospective analysis of ipilimumab-induced diarrhea and/or colitis: A single centre review. 2017
Risk-stratified multidisciplinary ambulatory management of malignant bowel obstruction (MAMBO) program for women with advanced gynecological cancer. 2017
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide. 2017
The PULSES project: Teaching the vital elements of code status discussions to oncology residents. 2017
Use of a marketing plan for recruitment to a lung cancer screening study. 2017
A person-centered e-proms multi-faceted intervention to improve patient experience and health outcomes: A multi-site implementation study in diverse ambulatory oncology practices. 2017
An evaluation of the breast cancer Well Follow-up Care Initiative using administrative databases: A new model of analysis. 2017
Developing and evaluating new models of care in hematology. 2017
Multidisciplinary cancer conferences as a forum for early identification of patients who can benefit from a palliative approach to care: INTEGRATE quality improvement project. 2017
Prognostic classification of muscle-invasive bladder cancer (MIBC) following radical cystectomy (RC) alone or with perioperative chemotherapy: Analysis of the U.S. National Cancer Database (NCDB). 2017
Identifying critical data elements for a provincial transition plan from a primary care perspective. 2017
Does the addition of biologic agents to chemotherapy in patients with unresectable colorectal cancer metastases result in a higher proportion of patients undergoing resection? A systematic review and meta-analysis. 2017
Incidence of venous thromboembolic events following major pelvic and abdominal surgery for cancer. 2017
Topographical incidence and survival analysis of gastrointestinal tract cancer in adolescent and young adults compared with older adults in the United States. 2017
A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. 2016
Patient-reported outcomes from MA.17R: A randomized trial of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. 2016
A randomized trial of a shorter radiation fractionation schedule for the treatment of localized prostate cancer. 2016
Anthracycline-induced cardiotoxicity in patients with early stage breast cancer: The Canadian cancer trials group (NCIC CTG) MA.21 experience. 2016
Anti-tumor activity, safety and pharmacokinetics (PK) of AGS15E (ASG-15ME) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC). 2016
CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. 2016
Comparing cervical cancer stage at diagnosis in immigrant women and long-term residents. 2016
Cytoreductive surgery (CRS) and heated intra-peritoneal chemotherapy (HIPEC) in the management of peritoneal carcinomatosis in a community setting. 2016
Developing and evaluating new models of care in hematology. 2016
Do women who self-report cognitive symptoms after breast cancer treatment have more cognitive impairment than those who do not report symptoms? A mechanistic cohort study with functional brain MRI. 2016
Dynamic angiogenic switch as predictor of response to chemotherapy+ bevacizumab in patients with metastatic colorectal cancer. 2016
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase II study. 2016
Evaluating the impact of Via Pathways (VP) on the adoption of changing treatment paradigms in metastatic hormone-sensitive prostate cancer (mHSPC). 2016
Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study. 2016
KEYNOTE-006 study of pembrolizumab (pembro) versus ipilimumab (ipi) for advanced melanoma: Efficacy by PD-L1 expression and line of therapy. 2016
Multi-site implementation of patient-reported outcome measures for personalized care and patient activation in symptom management. 2016
Phase II study of cabozantinib in recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago and California Phase II Consortia. 2016
Pre-screening test for clinical trials of Autologous γδ T lymphocyte therapy for advanced cancer. 2016
Readmission and emergency department visits in the peri-treatment period for head and neck cancers patients in Ontario. 2016
Reasons for delay in time to initiation of adjuvant chemotherapy (TTAC) for colon cancer (CC): Analysis from six academic centers in Ontario, Canada. 2016
Suggested reclassification strategy applied to intermediate and poor risk nonseminomatous germ cell tumors (NSGCT): A two-institution combined analysis. 2016
Using cognitive interviews and expert feedback to validate the Australian AYA Distress Thermometer and Problem Checklist for use in Canada. 2016
Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421. 2016
Initiative to streamline clinical trials (ISCT): Guidance for academic investigators/sponsors. 2016
Optimizing the collection and reporting of wait time data. 2016
Pathway map development as an approach to identifying priority areas for quality improvement in Ontario. 2016
Recommendations for the delivery of focal tumor ablation services. 2016
Standardizing architecture and governance of radiology clinical checklist development. 2016
Time trends in opioid use in cancer and noncancer patients: Observations from administrative data. 2016
Using a disease pathway management approach to improve the quality of breast cancer care in Ontario. 2016
Effects of a structured exercise program on physical activity and health-related fitness in colon cancer survivors: One year feasibility results from the NCIC CTG CO.21 (CHALLENGE) trial. 2016
PET-CT compared to no PET-CT in the management of potentially resectable colorectal cancer liver metastases: The costs implications of a randomized controlled trial 2016
Bridging the gap: The design of a survivorship curriculum for interspecialty collaboration. 2016
Integrating primary care and cancer care in survivorship: A collaborative approach. 2016
Neurocognitive function and psychological distress in young adults (YA) with cancer. 2016
Effect of anti-GRP78 autoantibodies on prostate cancer progression through tissue factor procoagulant activity. 2016
Impact of prior platinum on patients receiving salvage systemic therapy for advanced urothelial carcinoma (UC). 2016
Impact of single agent daily prednisone on survival and toxicities in post-docetaxel men with metastatic castration-resistant prostate cancer (mCRPC): An analysis of 2 phase III trials. 2016
Incidence, characteristics, and implications of thrombo-embolic events in patients with urothelial carcinoma of the bladder undergoing neoadjuvant chemotherapy. 2016
Integration of bone scan (BS) and computerized tomography (CT) findings as an endpoint to assess bone metastasis in metastatic castration-resistant prostate cancer (mCRPC). 2016
NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. 2016
Outcomes of advanced urothelial carcinoma following discontinuation of programmed death (PD)-1 or PD-ligand (L)-1 inhibitors. 2016
Patient reported outcomes in NRG Oncology/RTOG 0938, evaluating two ultrahypofractionated regimens (UHR) for prostate cancer (CaP). 2016
The RADICAL-PC trial. 2016
Development of provincial clinical standards for the province of Ontario. 2015
Meta-analysis: Risk of congestive heart failure (CHF) in selected targeted agents. 2015
Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study. 2015
A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma. 2015
A phase I study of BI 853520, an inhibitor of focal adhesion kinase (FAK), in patients with advanced or metastatic solid tumors. 2015
A phase I/II clinical trial of veliparib (ABT-888) and radiation followed by maintenance therapy with veliparib and temozolomide in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG): A Pediatric Brain Tumor Consortium Interim Report of Phase I Study. 2015
A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. 2015
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). 2015
A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic Non-Small Cell Lung Cancer (NSCLC) receiving standard chemotherapy: NCIC Clinical Trials Group IND.215. NCT01783197. 2015
A single institution experience of salvage therapy for locally advanced breast cancer: Treatments and trends. 2015
Blood and urine markers of metabolic dysfunction in colorectal cancer: a pilot study. 2015
Can oncology readmissions be reduced? The Cleveland Clinic experience. 2015
Cancer-related cognitive dysfunction (CRCD) and psychosocial development in young adult cancer survivors. 2015
Cardiovascular events in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors: A systematic review and meta-analysis. 2015
Evaluation of clinical and histological criteria and outcome in management of hereditary non-polyposis colorectal carcinoma (HNPCC). 2015
Expression of thyroid hormone receptor alpha (THR alpha) isoforms in triple negative breast cancer (TNBC) 2015
Externally validated improved 5-factor prognostic model in patients (pts) receiving salvage systemic therapy for advanced urothelial carcinoma (UC). 2015
Gemcitabine and platinum (GC) chemotherapy alone or with a taxane (GC-T) as first-line therapy for urothelial cancer (UC): A meta-analysis. 2015
Hepatitis B virus screening before adjuvant chemotherapy in patients with early stage breast cancer: A cost-effectiveness analysis. 2015
Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) 2015
Improving fitness after childhood cancer: A novel exercise clinic for pediatric oncology patients. 2015
Meta-analysis of the impact of single agent daily prednisone on outcomes and toxicities in metastatic castration-resistant prostate cancer (mCRPC). 2015
Modifiable metabolic markers c-peptide (C-PEP), highly sensitive c-reactive protein (hsCRP), leptin (LEP)] and lung cancer (LC) risk: A matched case-control study nested in the prostate, lung, colorectal and ovarian (PLCO) cancer screening study. 2015
NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers. 2015
Outcome of neurofibromatosis type 1 patients treated with first line vinblastine for optic pathway gliomas: A Canadian multicenter study. 2015
Phase 1 study with expansion cohorts of cabozantinib (C) + abiraterone (A) in metastatic castration resistant prostate cancer (mCRPC): Investigator-sponsored study. 2015
Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC). 2015
Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. 2015
Physicians' attitudes toward systematic symptom assessment and management: Results from all regional cancer centres in Ontario (Canada). 2015
Quality of life (QOL) in a phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 (NCT00820248). 2015
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. 2015
The role of PET-CT in treatment decision making for women with locally advanced cervical cancer. 2015
The role of biomarkers in improving clinical trial success: A study of 1,079 oncology drugs. 2015
Trends in demographics, incidence, and survival in children, adolescents and young adults (AYA) with melanoma: A Surveillance, Epidemiology and End Results (SEER) population-based analysis 2015
Tumor treating fields (TTFields): A novel treatment modality added to standard chemo- and radiotherapy in newly diagnosed glioblastoma—First report of the full dataset of the EF14 randomized phase III trial. 2015
Validation of correlation of RECIST changes with survival in metastatic castration-resistant prostate cancer (mCRPC). 2015
A randomized trial of 79.2Gy versus 70.2Gy radiation therapy (RT) for localized prostate cancer. 2015
Association of changes in measurable disease by RECIST with survival in metastatic castration-resistant prostate cancer (mCRPC). 2015
IND 205B: A phase II study of the PI3K inhibitor PX-866 and continued abiraterone/prednisone in patients with recurrent or metastatic castration resistant prostate cancer (CRPC) with PSA progression on abiraterone/prednisone. 2015
Impact of first-line cisplatin versus non-cisplatin based chemotherapy on progression-free survival in patients with advanced urothelial carcinoma previously treated with perioperative cisplatin based chemotherapy. 2015
Improved prognostic classification of patients receiving salvage systemic therapy for advanced urothelial carcinoma. 2015
The impact of renal cell carcinoma histopathological subtype on disease prognosis: A Canadian multi-institutional analysis. 2015
The proportion and characterization of patients with metastatic renal cell carcinoma who are never treated or have delayed treatment with targeted therapy: Results from a large prospective cohort. 2015
Treatment and clinical outcomes of patients with teratoma with somatic-type malignant transformation (TMT): An international collaboration. 2015
Identifying variables that predict poor tumor biology and suboptimal outcomes in patients treated with cytoreduction and HIPEC. 2015
Impact of radiotherapy duration on outcomes in patients with esophageal cancer treated with definitive concurrent radiotherapy and chemotherapy on RTOG trials 8501 and 9405. 2015
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity. 2014
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L), or their combination (T plus L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). 2014
A first-in-class, first-in-human phase I trial of KPT-330 (selinexor), a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. 2014
A phase 1 multicenter clinical trial of alemtuzumab and CHOP chemotherapy for peripheral T-cell lymphomas. 2014
A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia. 2014
A phase II randomized open-label study of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with weekly paclitaxel versus weekly paclitaxel in patients with platinum-resistant/refractory ovarian cancers. 2014
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). 2014
A randomized phase 3 trial of thalidomide and prednisone (TP) as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): An updated analysis of the NCIC Clinical Trials Group MY10 trial. 2014
A targeted intervention to improve awareness to molecular testing in NSCLC. 2014
Adjuvant radiation, androgen deprivation, and docetaxel for high-risk prostate cancer post-prostatectomy: Results of RTOG 0621. 2014
Androgen pathway manipulation and outcome in elderly men with non-small cell lung cancer: A population-based study from Ontario, Canada. 2014
Assessment of a dyspnea clinic for patients with thoracic malignancies 2014
Chemoradiation for locally advanced penile squamous cell carcinoma (PSCC): A multi-institution retrospective study. 2014
Correlation between phase 2 clinical trial design and subsequent phase 3 outcome. 2014
Do patients with small cell lung cancer (SCLC) who have chemotherapy initiated during a hospital admission benefit from therapy? 2014
Does routine symptom screening with the Edmonton Symptom Assessment System (ESAS) decrease emergency department visits in breast cancer patients undergoing adjuvant chemotherapy? 2014
Effect of continued imatinib (IM) in pts with detectable BCR-ABL after ≥ 2 years on study on deep molecular responses (MR): 36-month update from ENESTcmr. 2014
Evaluation of the adjuvant radiation treatment-effect heterogeneity using genomic signature for locoregional relapse and long-term outcome. 2014
Experimental fertility preservation (FP) interventions in prepubertal (PP) boys with cancer: A report on preferences of teenage cancer survivors, parents, and providers. 2014
External validation of nomogram to predict progression-free survival at 6 months (PFS6) in patients receiving salvage therapy for advanced urothelial carcinoma (UC). 2014
Final analysis of a large, open-label global early access protocol (EAP) with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after chemotherapy. 2014
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T -> L), or their combination T plus L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). 2014
Impact of health care professional interventions on completion of therapy in patients receiving high-dose interferon-alfa 2b adjuvant therapy for high-risk melanoma. 2014
Interobserver variation in predicting fracture risk in patients with long bone metastatic lesions. 2014
NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. 2014
Outcome of childhood T-cell acute lymphoblastic leukemia (T-ALL): Results from DFCI protocol 05-001. 2014
Patient eligibility and trial design for the salvage therapy of advanced urothelial carcinoma (UC) based on the impact of prognostic factors. 2014
Pharmacokinetic analysis of tamoxifen metabolites in premenopausal women with early breast cancer: A substudy of NCIC CTG MA.12 randomized clinical trial. 2014
Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors. 2014
Phase II study of XL184 (cabozantinib) in recurrent or metastatic endometrial cancer: A trial of the PMH, Chicago, and California Phase II Consortia. 2014
Phase II study of oral ENMD-2076 administered to patients with ovarian clear cell carcinoma: A trial of the Princess Margaret Phase II Consortium. 2014
Population-based evaluation of 21-gene assay in treatment decision making for early breast cancer in Ontario. 2014
Preoperative window-of-opportunity (WOO) study of dacomitinib (Dac) in patients (Pts) with resectable oral cavity squamous cell carcinoma (OCC): Generation of a gene expression signature (DGS) as a predictor of Dac activity. 2014
Prognostic and predictive significance of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial. 2014
Prognostic associations of 25OH vitamin D in NCIC CTG MA.21, a phase III adjuvant RCT of three chemotherapy regimens (EC/T, CEF, AC/T) in high-risk breast cancer (BC). 2014
Prognostic factors in hemangioendotheliomas (HE): Analysis based on the Surveillance, Epidemiology, and End Results (SEER) program. 2014
Prognostic potential of thyroid receptor TRα2 in breast cancer. 2014
Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). 2014
Reasons for delay in time to initiation of adjuvant chemotherapy for colon cancer: A multi-institution study. 2014
Results from an interdisciplinary palliative rehabiliation program for patients living with advanced cancer. 2014
The use of health-related quality of life outcomes in oncology practice: An international study. 2014
Using Magee equations to predict Oncotype DX recurrence scores: A potential cost and time saving strategy? 2014
Vitamin B12 (Vit B12) biochemical (BCH) deficiency (DEF) in non-diabetic breast cancer (BC) patients on NCIC CTG MA.32: A phase III randomized adjuvant BC trial comparing metformin (Met) to placebo (Pl). 2014
Contemporary outcomes of pT3 renal cell carcinoma: A Canadian multi-institutional experience. 2014
Impact of number of lines of prior chemotherapy in patients (pts) with advanced urothelial carcinoma (UC) receiving salvage therapy. 2014
Impact of prior platinum agent and site of primary in patients with advanced urothelial carcinoma (UC) receiving salvage therapy. 2014
Multi-institutional quality care initiative (QCI) to improve the care of patients with invasive bladder cancer (BlCa). 2014
Pain palliation as an oncology label indication: Lessons learned in custirsen phase III development. 2014
Positive surgical margins after partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer Information System database. 2014
Prognostic impact of C-reactive protein (CRP) in metastatic prostate cancer (MPC): A systematic review and meta-analysis. 2014
Simultaneous cone beam CT scanning during prostate radiotherapy to produce clinically useful images. 2014
The role of FSH in castration-induced adipogenesis and cardiovascular diseases: Highlighting differences between orchiectomy, GNRH agonists, and antagonists. 2014
Transurethral (TURP) biopsy of suspected anterior prostate cancers identified by MRI: Pilot study of a novel technique. 2014
A case series of Lynch syndrome-associated breast cancer. 2014
Functional BRM promoter polymorphisms, pancreatic adenocarcinoma risk, and survival. 2014
Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort. 2014
Access to personalized medicine: Factors influencing the use and value of gene expression profiling in treatment decision making. 2013
Identifying knowledge-translation opportunities in the treatment of locally advanced breast cancer. 2013
Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2. 2013
Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2. 2013
A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies 2013
A multicenter open-label phase II study of the efficacy and safety of ganitumab (AMG 479), a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) as second-line therapy in patients with recurrent platinum-sensitive ovarian cancer 2013
A phase I, dose-escalation trial of continuous and pulsed-dose afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: Final analysis. 2013
A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer. 2013
A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21) 2013
A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial 2013
A randomized phase II study of cediranib (CED) alone versus CED plus dasatinib (DAS) in patients (pts) with castration-resistant prostate cancer (CRPC). 2013
A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20. 2013
Bowel obstruction with stage IV cancer: The benefit of introduction of formal palliative care service. 2013
Canadian ALK (CALK): A pan-Canadian multicenter study to optimize and standardize ALK immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) for ALK gene rearrangements 2013
Characteristics of clinical trials for adolescent and young adult (AYA) cancer patients (pts) in Ontario. 2013
Characterization of patients who received prior chemotherapy for advanced breast cancer (ABC) in BOLERO-2. 2013
Clinical impact of EGFR mutation fraction and tumor cellularity in EGFR mutation positive NSCLC. 2013
Clinical management and resolution of stomatitis in BOLERO-2. 2013
Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole. 2013
Design of the AFFINITY study: A randomized phase III study of a novel clusterin inhibitor, custirsen, plus cabazitaxel/prednisone (CbzP) versus CbzP alone as second-line chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). 2013
Development of a practice consensus statement of the management of locally advanced breast cancer: Expert consensus and systematic review. 2013
Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC) 2013
Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial 2013
Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (rIL21) in patients with recurrent or metastatic melanoma (MM) 2013
Final results of a phase I study evaluating the combination of linsitinib, a dual inhibitor of insulin-like growth factor-1 receptor (IGF-1R), and insulin receptor (IR) with weekly paclitaxel (PAC) in patients (Pts) with advanced solid tumors. 2013
First-in-class, first-in-human phase I trial of KPT-330, a selective inhibitor of nuclear export (SINE) in patients (pts) with advanced solid tumors. 2013
Identification of knowledge translation opportunities in the treatment of locally advanced breast cancer: Results of a national survey of physicians 2013
Impact of response to prior chemotherapy (RTPC) on outcomes in second-line therapy for advanced urothelial carcinoma (UC): Implications for trial design. 2013
Impact of wait times on survival of women with uterine cancer. 2013
Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2. 2013
Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy 2013
NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer (CRPC). 2013
Nomogram to estimate the activity of second-line therapy for advanced urothelial carcinoma (UC) 2013
Ovarian cancer distribution of histology, stage, and screening performance 2013
Patient-reported physical, emotional, and social functioning in advanced breast cancer: Insights from BOLERO-2. 2013
Perioperative epidural analgesia and recurrence-free survival for ovarian cancer surgery: A retrospective analysis. 2013
Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr plus T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041) 2013
Prevalence, risk factors, treatment and outcomes of catheter-related thrombosis in patients with malignancies. 2013
Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study-NCT00811369. 2013
Rapid assessment of frailty prior to treatment of elderly colorectal cancer patients. 2013
Real-time clinical application of next-generation sequencing (NGS): Results from a multicenter program 2013
Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC). 2013
Results from a structured interprofessional palliative care rehabilitation program in oncology. 2013
Screening for Lynch syndrome in unselected women with endometrial cancer 2013
Simulating the cost-effectiveness of lung cancer screening by low-dose CT scan in Canada 2013
Switching patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with residual disease on long-term imatinib (IM) to nilotinib (NIL): ENESTcmr 24-mo follow-up 2013
The effect of surgery type on survival and recurrence in very young women with breast cancer. 2013
The first 10 years experience with genetic testing (GT) for BRCA1/2 mutations in a publicly funded program at a tertiary care teaching hospital in Ontario, Canada 2013
The role of FSH in castration-induced adipogenesis: Highlighting differences between orchiectomy, GNRH agonists, and antagonists. 2013
Thrombotic events in metastatic colorectal cancer patients treated with FOLFIRI plus bevacizumab. 2013
Weekly vinblastine in chemotherapy-naive children with unresectable or progressive low grade glioma: A Canadian cooperative study 2013
A multicenter population-based experience with abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC). 2013
Impact of baseline prognostic factors on progression-free survival at 6 months (PFS6) and response in patients receiving second-line therapy for advanced urothelial carcinoma (UC). 2013
Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy. 2013
Study of the impact of Charlson comorbidity index and hypertension on survival in patients with metastatic castration-resistant prostate cancer. 2013
Classification of a VUS in MLH1 using a combination of family segregation studies and protein biochemistry. 2013
Quality of life in a multicenter phase II trial of neoadjuvant full-dose gemcitabine, oxaliplatin, and radiation in patients with resectable or borderline resectable pancreatic adenocarcinoma. 2013
Reasons for delay in time to initiation of adjuvant chemotherapy (AC) for colon cancer (CC). 2013
Thrombotic events in patients with metastatic colorectal cancer treated with FOLFIRI plus bevacizumab. 2013
Does a quality-of-care problem exist? Cancer Care Ontario practice pattern data and the recommendations of two lung cancer practice guidelines. 2012
Patient-centered wait time measurement in Ontario. 2012
Robotic radiosurgery for the treatment of one to three brain metastases: A pragmatic application of cost-benefit analysis using willingness to pay. 2012
SAGE directory of cancer guidelines. 2012
The use of technology to improve the delivery process of ambulatory chemotherapy at the Odette Cancer Centre (OCC). 2012
Effects of everolimus (EVE) on disease progression in bone and bone markers (BMs) in patients (pts) with bone metastases (mets). 2012
Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. 2012
Safety of everolimus for women over age 65 with advanced breast cancer (BC): 12.5-month follow-up of BOLERO-2. 2012
Open-label phase III randomized controlled trial comparing taxane-based chemotherapy (Tax) with lapatinib (L) or trastuzumab (T) as first-line therapy for women with HER2+ metastatic breast cancer: Interim analysis (IA) of NCIC CTG MA.31/GSK EGF 108919. 2012
A phase I study of R04929097, an oral gamma secretase inhibitor, in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575) 2012
A phase II study of RO4929097 (RO), a gamma-secretase inhibitor, in advanced platinum (Pt)-resistant (R) ovarian cancer (OC): A study of the PMH, Chicago, and California phase II consortia 2012
A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). 2012
A phase III study of standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy (RT) with panitumumab in patients with locally advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) (NCIC Clinical Trials Group HN.6). 2012
A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29 2012
A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC) 2012
Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial. 2012
Assessment of the prognostic and predictive utility of the breast cancer index (BCI): An NCIC CTG MA.14 study. 2012
BOLERO-2: Everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone receptor-positive breast cancer. 2012
BOLERO-2: Health-related quality-of-life in metastatic breast cancer patients treated with everolimus and exemestane versus exemestane 2012
Cognitive function and fatigue in colorectal cancer (CRC) patients: A prospective longitudinal controlled study 2012
Do patient-reported symptoms predict for emergency department visits? A population-based analysis 2012
Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). 2012
Effects of everolimus (EVE) on disease progression in bone and bone markers (BM) in patients (pts) with bone metastases (mets). 2012
Everolimus for postmenopausal women with advanced breast cancer: Updated results of the BOLERO-2 phase III trial. 2012
Feasibility and acceptability of patient-reported outcomes data collection for clinical care following breast reconstruction. 2012
History of autoimmunity to predict clinical response to DNA methyltransferase inhibitors (DNMTI) in myelodysplastic syndromes (MDS), and MDS-derived acute myeloid leukemias (AML). 2012
Impact of concurrent (CON) and sequential (SEQ) radiotherapy (RT) with adjuvant aromatase inhibitors (AI) in early-stage breast cancer (EBC): NCIC CTG MA.27. 2012
Lapatinib in HER2+early breast cancer: Quality of life analysis 2012
Low-level laser therapy for chemotherapy-induced peripheral neuropathy. 2012
NCIC IND.190: A phase I trial of MK-0646 in combination with cisplatin and etoposide in extensive-stage small cell lung cancer (ES SCLC). 2012
Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSR SOC): A randomized, open-label phase II study. 2012
Once-daily oral afatinib (A) combined with pemetrexed (P) in patients (pts) with advanced solid tumors: A phase I dose escalation trial. 2012
Patient-reported cognitive impairments among women with breast cancer randomly assigned to hormonal therapy (HT) alone versus chemotherapy followed by hormonal therapy (C plus HT): Results from the Trial Assigning Individualized Options for Treatment (TAILORx) 2012
Patient-reported satisfaction with reconstructed breasts in the long-term survivorship period: Comparison of autologous and nonautologous breast reconstruction 2012
Positron emission tomography/computed tomography (PET/CT) for the diagnosis of recurrent cancer (PETREC): A multicenter, prospective cohort study. 2012
Pretreatment neurocognitive function (NCF) status in head and neck cancer (HNC) patients (pts) with comparison to control cohort 2012
Prognostic stratification of post-docetaxel metastatic castration resistant prostate cancer (mCRPC) from a phase III randomized trial 2012
Quantitative immunohistochemical (IHC) assessment of ataxia-telangiectasia mutated (ATM) in estrogen receptor (ER) negative early breast cancer (BC). 2012
Randomized trials of adjuvant tamoxifen versus tamoxifen and octreotide LAR in early-stage breast cancer: NCIC CTG MA.14 and NSABP B-29 2012
Results of a cluster randomized trial to evaluate a nursing lead supportive care intervention in newly diagnosed breast and colorectal cancer patients. 2012
Safety of everolimus for women over 65 years of age with advanced breast cancer (BC): 12.5-mo follow-up of BOLERO-2. 2012
Stage III NSCLC: How many patients are really suitable for radical treatment approaches? 2012
Stage III NSCLC: How many patients are really suitable for radical treatment approaches? 2012
Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib: ENESTcmr 12-month (mo) follow-up 2012
The value of personalizing medicine: Medical oncologists' and patients' perspectives on genomic testing of breast tumors in chemotherapy treatment decisions 2012
Time from prior chemotherapy (TFPC) as a prognostic factor in advanced urothelial carcinoma (UC) receiving second-line systemic therapy. 2012
Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC) 2012
Utility of the Edmonton Frail Scale (EFS) in identifying frail elderly patients during treatment of colorectal cancer (CRC). 2012
Vasomotor (VM) and musculoskeletal (MSK) symptoms and association with outcomes on extended adjuvant letrozole therapy: Analyses from NCIC CTG MA.17 2012
Changes in Cardiac Biomarkers During Doxorubicin Treatment of Pediatric Patients With High-Risk Acute Lymphoblastic Leukemia: Associations With Long-Term Echocardiographic Outcomes 2012
A randomized phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. 2012
Efficacy of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (mCRPC) exposed to prior ketoconazole (KC). 2012
Improving outcomes through the development of quality indicators in renal cell cancer. 2012
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). 2012
Testosterone suppression: Impact of testosterone level on disease progression in advanced prostate cancer. 2012
Perioperative chemotherapy for upper gastrointestinal cancer: Correlation between response to treatment and outcome. 2012
Survival analysis of PETCAM: A multicenter randomized controlled trial of PET/CT versus no PET/CT for patients with resectable liver colorectal adenocarcinoma metastases. 2012
Prediction of late recurrences by breast cancer index in the NCIC CTG MA.17 cohort. 2011
The effect of trastuzumab on pCR in locally advanced HER2-positive breast cancer. 2011
NCIC-CTG MA. 20: An intergroup trial of regional nodal irradiation in early breast cancer 2011
The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study 2011
A phase I study evaluating the combination of OSI-906, a dual inhibitor of insulin growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with weekly paclitaxel (PAC) in patients with advanced solid tumors. 2011
A phase I study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer. 2011
A phase III randomized trial of intermittent versus continuous androgen suppression for PSA progression after radical therapy (NCIC CTG PR.7/SWOG JPR.7/CTSU JPR.7/ UK Intercontinental Trial CRUKE/01/013). 2011
A phase III randomized trial of metformin versus placebo on recurrence and survival in early-stage breast cancer (BC) (NCIC Clinical Trials Group MA.32). 2011
A randomized phase III trial of magic mouthwash and sucralfate versus benzydamine hydrochloride for prophylaxis of radiation-induced oral mucositis in head and neck cancer. 2011
A randomized, double-blind, placebo-controlled cross over trial of the effect on quality of life (QOL) of continuing dexamethasone beyond 24 hours following moderately emetogenic chemotherapy in women with breast cancer. 2011
Ability of serum alkaline phosphatase (ALP) changes to complement PSA changes and predict survival in men with metastatic castration-resistant prostate cancer (mCRPC) receiving docetaxel and prednisone (DP). 2011
Adjuvant sunitinib (Su) for locally advanced esophageal cancer (LAEC): Results of a phase II trial. 2011
An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM) 2011
An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. 2011
Bevacizumab (Bev)-based therapy for patients (pts) with colorectal cancer (CRC): McGill University and Segal Cancer Centre experience. 2011
Canadian cancer risk management model: A new health policy tool useful in policy decisions related to lung cancer. 2011
Concordance with NCCN practice guidelines for local therapies as a measure of quality of care: Review of practice and identification of quality gaps. 2011
Cost-effectiveness of a survivorship care plan for breast cancer survivors. 2011
Do high symptom scores trigger clinical actions by providers? Assessing the effect of standardized symptom screening. 2011
Does removal of the primary tumor in patients with metastatic breast cancer improve either local control or overall survival? 2011
Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). 2011
Evaluation of second-line response to targeted therapy following progression on first-line cediranib, an oral pan-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), in advanced renal cell carcinoma (RCC). 2011
Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor-positive metastatic breast cancer who are refractory to letrozole or anastrozole: Preliminary results of the BOLERO-2 trial. 2011
Expected benefits versus actual outcomes in oncology phase III randomized controlled trials (RCTs). 2011
Funding academic oncology clinical trials. 2011
Global, multicenter, open-label, randomized phase II trial comparing gemcitabine (G) with. G plus AGS-1C4D4 (A) in patients (pts) with metastatic pancreatic cancer (mPC). 2011
How often are opioids prescribed for cancer patients reporting pain? Results of a population-based analysis. 2011
Impact of a change of body mass index (BMI) on outcome following adjuvant endocrine therapy, chemotherapy, or trastuzumab for breast cancer. 2011
Impact of increased use of adjuvant chemotherapy in non-small cell lung cancer: A population and economic assessment. 2011
Incident cancers in people with dysglycemia and other cardiovascular risk factors: Cohort study of the ORIGIN trial. 2011
Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. 2011
NCIC CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer. 2011
Neurocognitive function (NCF) in patients (pts) treated with chemo/bio-radiotherapy (C/B-RT) for head and neck cancers (HNC). 2011
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. 2011
Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192. 2011
Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN). 2011
Phase III study of taxane chemotherapy with lapatinib or trastuzumab as first-line therapy for women with HER2/neu-positive metastatic breast cancer (BC) (NCIC Clinical Trials Group (NCICCTG)MA.31/GSK EGF 108919). 2011
Randomized controlled trials (RCTs) in the era of molecular oncology: Methodology, biomarkers, and endpoints. 2011
Randomized trial of a lifestyle intervention for women with early-stage breast cancer (BC) receiving adjuvant hormone therapy: Initial results. 2011
Relationship of treatment-emergent symptoms and recurrence-free survival in the NCIC CTG MA.27 adjuvant aromatase inhibitor trial. 2011
Results of an Ontario Clinical Oncology Group (OCOG) prospective cohort study on the use of FDG PET/CT to predict the need for neck dissection following radiation therapy of head and neck cancer (HNC). 2011
Sponsor/research ethics boards (REB) communications about informed consent (IC) and time to local activation (LA): An NCIC CTG pilot study. 2011
The impact of dose intensity on the efficacy of gemcitabine plus carboplatin (GC) therapy for recurrent platinum-sensitive ovarian cancer (PSOC): A retrospective analysis of AGO-OVAR 2.5. 2011
The responsiveness of intrinsic subtypes to adjuvant anthracyclines versus nonanthracyclines in NCIC.CTG MA.5 randomized trial. 2011
The ultra-low molecular weight heparin (ULMWH) semuloparin for prevention of venous thromboembolism (VTE) in patients with cancer receiving chemotherapy: SAVE ONCO study 2011
Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. 2011
Translation of evidence into funding policy: An overview of guidelines from the Cancer Care Ontario's Program in Evidence-Based Care (PEBC). 2011
miR128 and LET-7 microRNAs as potential biomarkers for selection of patients with metastatic colorectal cancer candidate to cetuximab/panitumumab therapy. 2011
Assessment of two prognostic risk group methods to predict outcomes with docetaxel-based therapy in men with metastatic castration-resistant prostate cancer (mCRPC). 2011
Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. 2011
Initial report of RTOG 9601, a phase III trial in prostate cancer: Effect of anti-androgen therapy (AAT) with bicalutamide during and after radiation therapy (RT) on freedom from progression and incidence of metastatic disease in patients following radical prostatectomy (RP) with pT2-3,N0 disease and elevated PSA levels 2011
Multi-institutional quality-of-care initiative for nonmetastatic, muscle-invasive, transitional cell carcinoma of the bladder: Phase I. 2011
Neoadjuvant temsirolimus in high-risk renal cell carcinoma: Results from a single-center prospective study. 2011
Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC) 2011
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer 2010
A phase III, intergroup, randomized, double-blind, chemoprevention trial of selenium (Se) supplementation in resected stage I non-small cell lung cancer (NSCLC) 2010
A microarray approach to identify vorinostat-restored signaling pathways in leukemia cells. 2010
A phase I/II study of increasing doses of epirubicin (E) and docetaxel (D) plus pegfilgrastim (Pegf) for locally advanced (LABC) or inflammatory breast cancer (IBC): NCIC CTG MA.22. 2010
A phase II study of single-agent nab-paclitaxel as second-line therapy in patients with metastatic urothelial carcinoma. 2010
A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia 2010
A phase II trial of the Src kinase inhibitor AZD0530 in patients with metastatic or locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: A trial of the PMH phase II consortium. 2010
A pilot study of fosbretabulin with bevacizumab in recurrent high-grade gliomas. 2010
A prospective study to evaluate the role of 2-[18f] fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET), breast magnetic resonance imaging (MRI), and breast ultrasonography in monitoring tumor responses in patients with locally advanced breast cancer (LABC) undergoing neoadjuvant chemotherapy. 2010
A randomized crossover trial of venlafaxine (V) versus gabapentin (G) for hot flashes (HF) in breast cancer survivors. 2010
A randomized, double-blind, placebo-controlled phase II study of the efficacy and safety of farletuzumab (MORAb-003) in combination with weekly paclitaxel in subjects with platinum-resistant or refractory relapsed ovarian cancer. 2010
AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. 2010
Accuracy of computerized tomography (CT) imaging in predicting pathologic stage for patients undergoing surgery for transitional cell carcinoma (TCC) of the bladder. 2010
Adequacy of data provision and analysis in oncology phase III trials over the past 5 years. 2010
Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer. 2010
Breast cancer survivors perception of family physician (FP) or specialist as principal provider of routine follow-up care. 2010
Can elderly patients with recurrent ovarian cancer (ROC) be treated with a platinum-based doublet? Results from the CALYPSO trial. 2010
Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. 2010
Clinically significant delayed cardiac morbidity following ABVD chemotherapy for Hodgkin lymphoma: A population-based study 2010
Consistency in reporting of primary endpoints (PEP) from registration to publication for modern randomized oncology phase III trials. 2010
Early stopping rules employing early progression and response compared with conventional stopping rules in actual phase II trials. 2010
Final results of a meta-analysis testing HER2 and topoisomerase II alpha genes as predictors of incremental benefit from anthracyclines in breast cancer. 2010
Final results of a phase II study of voreloxin in women with platinum-resistant ovarian cancer. 2010
Inconsistencies among lists of cautioned/prohibited drugs in oncology phase I and phase II trials. 2010
Individualized patient care: Are we ready to meet the challenges for patients with lung cancer? 2010
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study. 2010
Interleukin-21 (IL-21) activity in patients (pts) with metastatic melanoma (MM). 2010
Natural history of castration-resistant nonmetastatic prostate cancer: Secondary analyses of a multicenter randomized controlled trial. 2010
Obesity, patient characteristics, and TIMP-1: Effects on non-bone RFS in NCIC CTG MA.14. 2010
Patterns of antidepressant use among women initiating tamoxifen therapy for the treatment of breast cancer in Ontario, Canada. 2010
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: Safety and response results from a multicenter phase II trial. 2010
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. 2010
Phase I trial of OGX-427, a 2'methoxyethyl antisense oligonucleotide (ASO), against heat shock protein 27 (Hsp27): Final results. 2010
Phase I/II study of low-dose cytarabine (LDAC) with sorafenib as first-line therapy of elderly patients with AML or high-risk myelodysplastic syndrome (MDS). 2010
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methothrexate, and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC). 2010
Phase II study of neoadjuvant and adjuvant gefitinib (G) with neoadjuvant chemoradiotherapy (CRT) in operable esophageal adenocarcinoma (EAC). 2010
Phase II study of vorinostat in patients with advanced melanoma. 2010
Phase II trial of the irreversible oral pan-HER inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) 2010
Preventing patupilone-induced diarrhea with high-dose corticosteroids. 2010
Prospective change in 25-OH vitamin D levels over long-term follow-up and health outcomes in breast cancer survivors. 2010
Survival of non-small cell lung cancer (NSCLC) patients in a randomized trial as predicted by the FDG-PET standardized uptake value (SUV). 2010
Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for early-stage breast cancer in postmenopausal women: Update of NCIC CTG MA14 trial. 2010
Temsirolimus (TEM) in endometrial cancer: Predictors of response and progression. 2010
Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. 2010
Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer. 2010
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163 2009
A phase II study evaluating the safety and efficacy of patupilone in patients with platinum refractory/resistant ovarian, primary fallopian, or peritoneal cancer 2009
A phase II study of GW786034 (pazopanib) in patients with recurrent or metastatic invasive breast carcinoma: Results after completion of stage I: A trial of the Princess Margaret Hospital Phase II Consortium 2009
A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer 2009
A phase II study of patupilone in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) who have progressed after docetaxel 2009
A phase II study of single agent abraxane as second-line therapy in patients with advanced urothelial carcinoma 2009
A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium 2009
A phase II trial of voreloxin in women with platinum-resistant ovarian cancer 2009
A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer 2009
Anthracyclines in basal breast cancer: The NCIC-CTG trial MA5 comparing adjuvant CMF to CEF 2009
Comparison of randomized phase II studies (RP2s) and subsequent randomized controlled studies (RCTs) using identical systemic therapies 2009
Correlation of N-telopeptide of type I collagen (NTX) with survival and fractures in patients (pts) with bone metastases from renal cell carcinoma (RCC) 2009
Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer 2009
Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada 2009
Dalteparin low molecular weight heparin (LMWH) in ovarian cancer: A phase II randomized study 2009
Differences in uptake of postoperative adjuvant chemotherapy for lung cancer: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study 2009
Economic guidelines for oncology products: Adaptation of the Canadian Agency for Drugs and Technologies in Health (CADTH) technology assessment guidance document 2009
Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide (B-CTX) in postmenopausal women 2009
Effect of geographic distance from a cancer centre on choice of systemic therapy in metastatic colorectal cancer 2009
Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): A prospective randomized trial (PET START) 2009
Importance of stratification when measuring quality of care: Results from the Project for an Ontario Women's Health Evidence-Based Report Card (POWER) study 2009
Integration between primary care providers and the cancer system: Gaps and opportunities 2009
Interim analysis of a phase II trial of 5-azacitidine (5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer (NSCLC) 2009
Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer 2009
OGX-427, a 2 ' methoxyethyl antisense oligonucleotide (ASO), against HSP27: Results of a first-in-human trial 2009
PET-CT compared to invasive mediastinal staging in non-small cell lung cancer (NSCLC) 2009
Phase I study of intravenous decitabine in combination with oral vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas (NHL) 2009
Phase II study of AVR118 in the management of cancer related anorexia/cachexia 2009
Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC) 2009
Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer 2009
Primary tumor and patient characteristics in breast cancer as predictors of adjuvant chemotherapy regimen: A regression model 2009
Safety and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): Analysis of MO19391 according to CT 2009
Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial 2009
The McGill Cancer Nutrition and Rehabilitation Program 2009
The management of dysphagia in esophageal cancer patients undergoing neoadjuvant chemotherapy: Is invasive tube feeding required? 2009
Tolerability and efficacy of first-line bevacizumab (B) plus chemotherapy (CT) in elderly patients with advanced breast cancer (aBC): Subpopulation analysis of the MO19391 study 2009
Treatment and outcome of patients with brain metastases from non-small cell lung cancer (NSCLC) 2009
Trends in the application of dynamic allocation methods in multiarm cancer clinical trials 2009
Two-years biochemical failure-free survival following high intensity focused ultrasound (HIFU) for localized prostate cancer: Prospective single center study of 196 patients 2009
Willingness of breast cancer survivors to participate in a randomized controlled trial (RCT) of digital mammography with or without magnetic resonance imaging (MRI) as breast cancer (BC) surveillance: A feasiblity study 2009
Comparison of Referring and Final Pathology for Patients With Non-Hodgkin's Lymphoma in the National Comprehensive Cancer Network 2008
A comparison of internet-based models assessing the likelihood of a BRCA mutation 2008
A multicenter, open-label, phase I/II study in patients with unresectable stage III non-small cell lung cancer (NSCLC) treated with L-BLP25: 2-year survival and safety results 2008
A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) 2008
A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC) 2008
A phase II prospective study of standardized steroid dosing for patients with brain metastases undergoing whole brain radiotherapy 2008
A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poor-risk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy 2008
A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial 2008
A phase II study of patupilone in patients with metastatic hormone refractory prostate cancer (HRPC) who have progressed after docetaxel 2008
A phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b 2008
A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer 2008
A phase II trial of the histone deacetylase inhibitor belinostat (PXD101) in patients with platinum resistant epithelial ovarian tumors and micropapillary/borderline (LMP) ovarian tumors. A PMH phase II consortium trial 2008
A prospective study evaluating 18F-Fluorodeoxyglucose (18FDG) positron emission tomography (PET) in the assessment of axillary nodal spread in women undergoing sentinel lymph node biopsy (SLNB) for breast cancer 2008
A randomized controlled trial (RCT) of 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) versus conventional imaging (CI) in staging potentially resectable non-small cell lung cancer (NSCLC) 2008
Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium 2008
Anticoagulation and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of Canada Clinical Trials Group 2008
Clinical safety and efficacy of 90yttrium resin microspheres alone in unresectable, heavily pre-treated colorectal liver metastases: results of a phase II trial 2008
Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials 2008
Construction of tissue micro array from prostate needle biopsies using vertical clustering re-arrangement technique 2008
Correlation of computerized tomography measurement of visceral adiposity with plasma adiponectin levels and presence of metastatic disease in patients with clear cell renal cell carcinoma 2008
Correlation of deviation from intended cisplatin (CDDP) dose intensity with outcome in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) receiving concurrent chemoradiation (CRT) 2008
Effects of nutritional intervention in non-small cell lung cancer patients with different levels of systemic inflammation 2008
Expanded phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors 2008
Feasibility and efficacy of second-line chemotherapy at recurrence for pediatric low-grade gliomas: A comparative population-based study 2008
Frequency of vitamin D (Vit D) deficiency at breast cancer (BC) diagnosis and association with risk of distant recurrence and death in a prospective cohort study of T1-3, N0-1, M0 B 2008
Generalizability of results from oncology clinical trials: Toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer 2008
Health preference instruments in a breast cancer population: Is there a ceiling effect when compared to the quality-of-life instruments? 2008
Impact of a community-based pediatric oncology nursing model 2008
Improving the flow and scheduling of patients in the Systemic Treatment Program at the Odette Cancer Centre: Decreasing patients wait-times 2008
Influence of independent review committees (IRC) on assessment of response rate and progression free survival in phase III clinical trials 2008
Lower plasma adiponectin levels are associated with larger tumor size and metastasis in clear cell carcinoma of the kidney 2008
MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC) 2008
Meta-analysis examining the efficacy of serotonin and/or norepinephrine reuptake inhibitors in the treatment of women with hot flashes 2008
Meta-analysis of effects of zoledronic acid (ZOL) on survival in metastatic bone disease (MBD): Survival in patients with high bone turnover 2008
NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam plus octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer 2008
Patterns of adjuvant systemic therapy in elderly with breast cancer (BC) 2008
Pharmacokinetic (PK) analysis of a phase I trial investigating continuous treatment with the angiokinase inhibitor BIBF 1120 combined with pemetrexed in previously treated patients with non-small cell lung cancer (NSCLC) 2008
Phase I trial of 5-azacitidine (5AC) and SNDX-275 in advanced lung cancer (NSCLC) 2008
Presentation of non-final results of randomized controlled trials (RCTs) at major oncology meetings 2008
Progression free survival in patients with metastatic and recurrent renal cancer treated with sorafenib—Single center experience 2008
Sex, income and age-related differences in colorectal cancer care: results from the Project for an Ontario Women's Health Evidence-based Report Card (POWER) study 2008
Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): A phase II trial of the University of Chicago, PMH, and California Phase II Consortia 2008
Survival benefits of zoledronic acid in patients with bone metastases from non-small cell lung cancer and high NTX levels: The role of BALP 2008
The prognostic value of pain scores for clinical outcomes in advanced breast cancer and prostate cancer 2008
The quality of informed consent forms for oncology clinical trials 2008
The unclear zone in phase II clinical trials 2008
Triple-negative receptor status and prognosis in the NCIC CTG MA. 21 adjuvant breast cancer trial 2008
Use of elevated bone turnover to predict bone metastasis 2008
Consistency of Phase III Clinical Trial Abstracts Presented at an Annual Meeting of the American Society of Clinical Oncology Compared With Their Subsequent Full-Text Publications 2008
Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer 2007
Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma 2007
A phase I study of vorinostat (VOR) in combination with capecitabine (CAP) in patients (pts) with advanced solid tumors 2007
A phase III adjuvant trial of sequenced EC plus filgrastim plus epoetin-alpha followed by paclitaxel compared to sequenced AC followed by paclitaxel compared to CEF in women with node-positive or high-risk node-negative breast cancer (NCIC CTG MA.21) 2007
A randomized trial of computer and pamphlet-based versions of the Decision Board (DB) 2007
A review of 565 phase II trial abstracts from ASCO 2005: Design characteristics of contemporary trials evaluating cytotoxic versus non-cytotoxic regimens 2007
A single agent, phase I pharmacodynamic study of nimotuzumab (TheraClM-h-R3) in patients with advanced refractory solid tumors 2007
Adherence to surveillance guidelines following curative resection for stage II and III colorectal cancer 2007
CA-125 response as a marker of clinical benefit in patients with recurrent ovarian cancer treated with gemcitabine and sorafenib-A trial of the PMH Phase II Consortium 2007
Cognitive function and fatigue in cancer patients after chemotherapy: A longitudinal cohort study in patients with colorectal cancer (CRC) 2007
Correlation between changes in 2-or 3-year disease-free survival (DFS) and 5-year overall survival (OS) in adjuvant breast cancer trials from 1966-2006 2007
Identification of cancer care and protocol characteristics associated with recruitment rate in breast cancer clinical trials in Ontario 2007
Initial versus recent outcomes with a non-risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT) 2007
Nomograms to predict serious adverse events (SAEs) in patients (pts) enrolled in phase II clinical trials of molecularly targeted agents (MTAs) 2007
Phase II stopping rules employing response rates and early progression 2007
Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium 2007
Prospective study of specialist oncology community nursing resulting in improvements in key patient supportive care outcomes 2007
Regional models of care for systemic therapy: Standards for organization and delivery 2007
Sustainable improvement in quality indicators in Ontario's surgical oncology program (SOP) 2007
The quality of phase I trial (P1T) abstracts submitted to ASCO meetings 2007
Use of systemic therapy in women with recurrent ovarian cancer-Development of a national clinical practice guideline 2007
W Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival of the TAX 327 study 2007
What can physicians do to promote patient involvement in decision making (DM) in the oncology consultation? 2007
Evaluation of Cognitive Function Associated With Chemotherapy: A Review of Published Studies and Recommendations for Future Research 2007
Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study 2007
Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17 2007
Impact and Perceptions of Mandatory Tumor Biopsies for Correlative Studies in Clinical Trials of Novel Anticancer Agents 2006
A comparison of BRCA1 and BRCA2 risk assessment models. 2006
A comparison of patient and physician attributes that promote patient involvement in treatment decision making in the oncology consultation. 2006
A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts. 2006
A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR plus IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC) 2006
A phase II study of lapatinib in recurrent or metastatic EGFR and/or ErbB2 expressing adenoid cystic (ACC) and non-ACC malignant tumors of the salivary glands (MSGT). 2006
A phase III, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR plus IFN in the treatment of first-line, poor-prognosis patients with advanced renal cell carcinoma. 2006
A randomized controlled trial (RCT) of long-term follow-up for early stage breast cancer comparing family physician to specialist care: A report of secondary outcomes. 2006
A randomized controlled trial to evaluate the impact of an educational DVD an cancer patients considering participation in a phase I clinical trial. 2006
Agreement between physicians and patients about what constitutes shared decision making. 2006
Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. 2006
Bortezomib is active in Waldenstrom's Macroglobulinemia (WM) - Results of a National Cancer Institute of Canada (NCIC) phase II study in previously untreated or treated WM. 2006
Cognitive impairment associated with chemotherapy for breast cancer: An exploratory case-control study. 2006
Cytokine levels in patients (pts) with localized colorectal cancer (CRC) after surgery and their relationship to fatigue and cognitive function. 2006
Delays in diagnosis and initiating treatment for patients with lung cancer. 2006
Dose banding of chemotherapy doses at the Juravinski Cancer Centre. 2006
Effect of zoledronic acid (Z) treatment based on serum parathyroid hormone (PTH) levels in patients (pts) with malignant bone disease. 2006
Effects of adjuvant chemotherapy on the protein C anticoagulant pathway in patients with early stage breast cancer. 2006
Effects of zoledronic acid on survival in patients with lung cancer and high baseline N-telopeptide (NTX) levels: Stratified by baseline bone alkaline phosphatase (BALP). 2006
Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCICCTG MA.14 adjuvant breast cancer trial. 2006
Left ventricular function following adjuvant chemotherapy for breast cancer: The NCICCTG MA5 experience. 2006
Long-term results of concurrent gemcitabine (G) and radiotherapy (GRT) for locally advanced (LA) or high-risk resected (R) pancreatic cancer. 2006
Misunderstanding of prostate cancer (CaP) among African American (AA) men of lower socioeconomic status (Lo-SES). 2006
Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCICIND 160. 2006
NCICCTG MA.17: Tolerability of letrozole among ethnic minority women. 2006
Neuroendocrine tumors (NET) of the gastrointestinal tract: A decade of experience at the Princess Margaret Hospital. 2006
Pegylated Liposomal Doxorubicin and Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer: A Multicenter Phase II Trial 2006
Phase II study of neoadjuvant docetaxel and androgen suppression (AS) plus radiation therapy (RT) for high-risk localized prostate cancer (HRLCaP). 2006
Phase II study of sorafenib (BAY 43-9006) in combination with gemcitabine in recurrent epithelial ovarian cancer: A PMH phase II consortium trial. 2006
Predicting recurrence following post-chemotherapy retroperitoneal lymph node dissection for residual fibrosis or teratoma. 2006
Predictors of clinical outcome in patients with bone metastases from prostate cancer. 2006
Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). 2006
Quality of life (QOL) of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) following treatment with docetaxel or mitoxantrone in the TAX-327 study. 2006
Randomized clinical trials in oncology stopped early for benefit (RCTSEB). 2006
Understanding and preferences for receiving prognostic information: A comparison of the views of Australian and Canadian patients with metastatic cancer 2006
Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer 2006
Comparison of Outcomes of Phase II Studies and Subsequent Randomized Control Studies Using Identical Chemotherapeutic Regimens 2005
Randomized Phase IIB Trial of BLP25 Liposome Vaccine in Stage IIIB and IV Non–Small-Cell Lung Cancer 2005
Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid 2005
A multicenter, phase II study of cisplatin, irinotecan and epirubicin (PIE) administered every 3 weeks in patients with unresectable, locally advanced/metastatic cervical carcinoma. 2005
A phase I study of a second generation antisense oligonucleotide to clusterin (OGX-011) in combination with docetaxel: NCICCTG IND. 154. 2005
A phase II study of BAY 43-9006 in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC). 2005
A phase II study of UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A Princess Margaret Phase II Consortium Trial 2005
A phase II trial of temsirolimus in metastatic neuroendocrine carcinomas (NECs). 2005
A study of surveillance mammography (SM) of the contralateral breast (CLB) following total mastectomy (TM) for breast cancer (BC). 2005
ABREAST: A new global registry of adjuvant strategies in patients with early stage breast cancer. 2005
Determinants of preferences for starting extended adjuvant letrozole (L) in postmenopausal women following five years of tamoxifen. 2005
Dose reduced first-line capecitabine monotherapy in older and less fit patients with advanced colorectal cancer (ACRC) 2005
Evaluation of responsiveness to change to psychosocial group therapy (PGT) and to the process of dying of psychosocial and quality of life (QOL) measures. 2005
HGS-ETR1, a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 1 (TRAIL-R1) in patients with advanced solid cancer: Results of a phase 1 trial. 2005
Natural history of rising serum PSA in men with castrate nonmetastatic prostate cancer. 2005
Phase I-II study of DaICM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC). 2005
Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors. 2005
Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the princess margaret hospital [PMH] phase II consortium. 2005
Phase II study of oblimersen sodium and rituximab in patients with recurrent B-cell non-Hodgkin's lymphoma. 2005
Predictive value of eTag dimerization assay in patients with metastatic colorectal cancer treated with erlotinib. 2005
Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). 2005
Randomized, phase III trial comparing irinotecan/cisplatin (IP) with etoposide/cisplatin (EP) in patients (pts) with previously untreated, extensive-stage (ES) small cell lung cancer (SCLC). 2005
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results 2005
S9900: A phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): Preliminary results. 2005
Subgroup analysis of a phase III trial of doxorubicin vs doxorubicin plus tesmilifene in advanced breast cancer (ABC): Tesmilifene survival benefit focused on patients with more aggressive disease. 2005
Suppression of bone turnover markers by zoledronic acid and correlation with clinical outcome. 2005
The effect of doxycycline on bone turnover and tumor markers in breast cancer (BC) patients with skeletal metastases. 2005
The effect of zoledronic acid (Zol) dose and infusion rate on pharmacolkinetics (PK), pharmacodynamics (PD), and renal function in patients (pts) with multiple myeloma (MM) or prostate cancer (PC) and bone metastases. 2005
The impact and perception of mandatory tumor biopsies (Bx) for correlative studies in clinical trials of novel anticancer agents. 2005
The prognostic effect of lipids on early-stage breast cancer (BC) outcome. 2005
What are the supportive care service needs of recently diagnosed cancer patients? Results of a population based study 2005
Willingness of older people with cancer to participate in cancer clinical trials is not a barrier to accrual. 2005
Combining Gemcitabine and Capecitabine in Patients With Advanced Biliary Cancer: A Phase II Trial 2005
Why Cancer Patients Enter Randomized Clinical Trials: Exploring the Factors That Influence Their Decision 2004
A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer. 2004
A phase II trial of the proteosome inhibitor PS-341 in patients with metastatic colorectal cancer 2004
A randomized controlled trial (RCT) of routine follow-up for early stage breast cancer: A comparison of primary care versus specialist care. 2004
A randomized phase I clinical and biologic study of two schedules of BAY 43-9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study. 2004
Assessment of quality of life (QOL) in MA.17, a randomized placebo-controlled trial of letrozole in postmenopausal women following five years of tamoxifen 2004
Association of young age and chemotherapy with psychosocial distress and health-related quality of life (HRQOL) during the first year after breast cancer (BC). 2004
Cancer patients and the Internet: A randomized controlled trial (RCT) evaluating an intervention to facilitate physician and patient information exchange from the Internet (I). 2004
Characteristics of out-of-pocket costs for cancer patients in Ontario, Canada 2004
Chemo-radiotherapy versus radiotherapy alone for nasopharyngeal carcinoma: A meta-analysis of 78 randomized controlled trials (RCTs) from English and non-English databases. 2004
Comparison of outcomes of phase II trials (P2Ts) and subsequent randomized control trials (RCTs) using identical therapeutic regimens. 2004
Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: A National Cancer Institute of Canada Clinical Trials Group Study: MY.7. 2004
Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies. 2004
Ontario Cancer Research Ethics Board (OCREB): A central research ethics board initiative. 2004
Patterns of trastuzumab (T) use in three Canadian provinces. 2004
Phase I study of a fully human monoclonal antibody to the tumor necrosis factor-related apoptosis-inducing ligand death receptor 4 (TRAIL-R1) in subjects with advanced solid malignancies or non-Hodgkin's lymphoma (NHL) 2004
Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCICCTG IND-148. 2004
Practitioner feedback an clinical practice guidelines developed by Cancer Care Ontario's Lung Disease Site Group: Extending the circle of involvement. 2004
Prognostic factors in early stage head and neck squamous cell carcinoma (HNSCC) patients in a prospective clinical trial. 2004
Prognostication using serum levels of components of the folate metabolic pathway in patients (PTS) treated with capecitabine for advanced colorectal cancer (ACRC). 2004
Retrospective analysis of treatment practices for elderly cancer patients (Pts) in Ontario, Canada 2004
Slow intravenous infusion of PV701, an oncolytic virus: Final results of a phase I study 2004
Supportive care in cancer. Who does what? 2004
The intensity of CEACAM-1 expression in melanoma patients and the timing of treatment with recombinant human interferon & 2b showed correlation with survival. 2004
Thromboembolism (TE) in children with acute lymphoblastic leukemia (ALL) treated on Dana Farber Cancer Institute (DFCI) protocols: Effect of dose and type (prednisone versus dexamethasone) of steroids used. 2004
Tolerability of the Intergroup 0099 regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status. 2004
Zoledronic acid reduces the need for radiation to bone in patients with breast or prostate cancer metastatic to bone: A survival-adjusted cumulative incidence analysis. 2004
Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19 2004
Are Older Cancer Patients Being Referred to Oncologists? A Mail Questionnaire of Ontario Primary Care Practitioners to Evaluate Their Referral Patterns 2003
Enzyme-linked immunoabsorbent assay-detected p53 protein accumulation: a prognostic factor in a large breast cancer cohort. 1998

Journal of Clinical Oncology Journal

Overview

publication venue for

has subject area

Identity

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)